Search
Nervgen Pharma Ord Shs
NGENAdd to Watchlist
1.670USD
-0.050-2.91%
Close 07-23 16:00（ET）Quotes delayed by 15 min
133.01MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Nervgen Pharma Ord Shs is 8.22, ranking 149 out of 386 in the Biotechnology & Medical Research industry.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
10.213
Target Price
+473.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
Nervgen Pharma Ord Shs
NGEN
9
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
How have Nervgen Pharma Ord ShsNGEN's recent earnings per share performed?
The market expectation was USD -0.02, while Nervgen Pharma Ord ShsNGEN's earnings per share (EPS) for the previous quarter was USD -0.27. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for Nervgen Pharma Ord Shs?
Based on the ratings of Nervgen Pharma Ord Shs's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.